Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Revance management to meet virtually with Mizuho.
Virtual Meeting to be held on December 7 hosted by Mizuho.
(We might not have access to this since it is not listed on RVNC's EVENTS page.)
REVANCE AESTHETICS - new web site -incorporates older information +
This PRESTIGE MARKET was discussed Dec. 1 at the Piper Sandler 32nd Annual Virtual Healthcare Conference. CEO stated RVNC plans to charge additional premiums for DAXI, once approved. Also, increase their sales force to approximately 130 from 100.
https://revanceaesthetics.com/
From a FON (Family Office Networks) report:
https://familyofficenetworks.com/fon-featured-news/revance-therapeutics-the-prestige-medical-aesthetic-biotech/
REVANCE AESTHETICS - new web site - incorporates older information +
This PRESTIGE MARKET was discussed Dec. 1 at the Piper Sandler 32nd Annual Virtual Healthcare Conference. CEO stated RVNC plans to charge additional premiums for DAXI, once approved. Also, increase their sales force to approximately 130 from 100.
https://revanceaesthetics.com/
From a FON (Family Office Networks) report:
https://familyofficenetworks.com/fon-featured-news/revance-therapeutics-the-prestige-medical-aesthetic-biotech/
Revance Therapeutics Inks Long-Term Office Lease in Nashville for New Headquarters
Biotech Firm to Take Over 40,000 Square Feet in Endeavor's Gulch Union Office Tower
https://www.costar.com/article/341648163/revance-therapeutics-inks-long-term-office-lease-in-nashville-for-new-headquarters
HintMD and Marcus Medical Spa
FWIW - Excerpts:
Brokerage Cowen says the U.S. FDA's call to defer its decision on RVNC's experimental frown line treatment was anticipated due to COVID-19-related travel restrictions
** Cowen says a survey of clinicians indicates that co's treatment is differentiated and "poised to disrupt" the market for products to treat forehead wrinkles, such as AbbVie's Botox.
** FDA did not indicate there were any other review issues beyond on-site inspection - RVNC
** Cowen, which rates the stock "outperform", expects the delay to be "modest"; Says facility inspection seems to be the only outstanding issue which could be resolved shortly.
Morgan Stanley
FWIW - Excerpts:
Brokerage Cowen says the U.S. FDA's call to defer its decision on RVNC's experimental frown line treatment was anticipated due to COVID-19-related travel restrictions
** Cowen says a survey of clinicians indicates that co's treatment is differentiated and "poised to disrupt" the market for products to treat forehead wrinkles, such as AbbVie's Botox
** FDA did not indicate there were any other review issues beyond on-site inspection - RVNC
** Cowen, which rates the stock "outperform", expects the delay to be "modest"; Says facility inspection seems to be the only outstanding issue which could be resolved shortly.
Morgan Stanley
H.C. Wainwright keeps Buy rating on Revance, says FDA news 'not surprising'
H.C. Wainwright analyst Douglas Tsao said Revance's announcement that the FDA deferred the approval decision for Daxi's BLA from its PDUFA date of November 25 was "not surprising" given how a required site inspection was unable to be scheduled. While "obviously disappointing," Tsao contends that it is important to recognize this is not a complete response letter and not a reflection of a problem with the Daxi BLA, but a reflection of travel restrictions impacting the FDA. He reiterates a Buy rating on Revance shares with a $33 price target.
H.C. Wainwright keeps Buy rating on Revance, says FDA news 'not surprising'
H.C. Wainwright analyst Douglas Tsao said Revance's announcement that the FDA deferred the approval decision for Daxi's BLA from its PDUFA date of November 25 was "not surprising" given how a required site inspection was unable to be scheduled. While "obviously disappointing," Tsao contends that it is important to recognize this is not a complete response letter and not a reflection of a problem with the Daxi BLA, but a reflection of travel restrictions impacting the FDA. He reiterates a Buy rating on Revance shares with a $33 price target.
Read more at:
https://thefly.com/n.php?id=3202839
Bay Area biotech moving HQ here
Public company leases space on two floors of new Gulch tower -
Nov. 24
https://www.nashvillepost.com/business/health-care/article/21144654/bay-area-biotech-moving-hq-here
Enanta price target lowered to $45 from $52 at RBC Capital
Read more at:
https://thefly.com/n.php?id=3202032
Marlborough, Ma signs off on TIF for California biotech Revance - Nov. 17
MARLBOROUGH — A California-based biotech company will soon call Marlborough home.
Revance Therapeutics Inc.’s request for a 15-year tax increment financing deal with the city was approved by city councilors on Monday, paving the way for the company to build a new facility for commercial aseptic fill operations and research and development on Campus Drive. The company's headquarters will remain in California.
The Economic Assistance Coordinating Council must also approve the deal.
Under the proposed tax increment financing deal, the real property exemption percentage would be 100% in fiscal 2022 and 2023, drops to 90% in fiscal years 2024 and 2025 and 85% in fiscal 2026. The real property exemption percentage will drop 5% each year from fiscal 2025 to fiscal 2031 and then 10% each year until the end of the deal in fiscal 2036.
Marlborough has nine active tax increment financing deals with companies.
“The city claims to be business-friendly and this is why,” said City Councilor David Doucette.
Revance — which employs 460 people — has been looking to expand in recent years and initially considered San Francisco’s Bay Area for a new facility. The company had been considering other areas in Massachusetts — including Northborough — and Ireland before selecting Marlborough.
Company officials said Revance’s primary objectives were to find a location that meets all operational requirements at a site where the company can hire and retain exceptional talent, lower operating costs, operate in a stable and business-friendly environment with an improved tax structure and provide flexibility for future growth.
Doucette last week called the proposed Campus Drive site a “marquee location.” City Councilor Donald Landers said landing a company like Revance will make Marlborough the envy of many surrounding communities.
“I think this tenant will be a home run,” said Landers. “This is a good opportunity for us.”
City leaders have said the deal will bring more high-paying jobs to Marlborough, a new building to the city and eventually generate much-needed tax revenue.
“This is currently a parking lot,” Doucette said of the planned site of Revance’s new facility.
Marlborough, in recent years, has attracted several life science and biotech companies, bringing hundreds of new jobs to the region. The company plans to hire 76 on-site full-time employees at the Marlborough facility by fiscal 2025 under the terms of the tax deal.
The city is rated a Platinum BioReadyTM Community by the Massachusetts Biotechnology Council, which puts Marlborough among the most favorable biotech destinations in the state. Only 7% of Massachusetts communities have achieved platinum status.
https://www.metrowestdailynews.com/story/news/2020/11/17/revance-therapeutics-open-new-facility-marlborough/6322678002/
Enanta Pharmaceuticals to Present at Upcoming Investor Conferences
Wed, November 18, 2020, 7:02 AM EST
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two upcoming conferences:
Evercore ISI 3rd Annual Virtual HealthCONx Conference, Fireside Chat at 9:15 a.m. ET on December 1, 2020
Piper Sandler 32nd Annual Virtual Healthcare Conference, One-on-One Meetings on December 2, 2020, with a Fireside Chat available to view beginning November 25
https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-to-Present-at-Upcoming-Investor-Conferences/default.aspx
California-based biotech company Revance takes step toward opening facility in Marlborough - Nov. 14
MARLBOROUGH – A California biotech company’s effort to open a facility in Marlborough has taken a step forward.
Finance Committee members on Monday signed off on Revance Therapeutics Inc.’s request for a 15-year tax increment financing deal to build a facility for commercial aseptic fill operations and research and development on Campus Drive. The full City Council is expected to vote on the tax increment financing deal in coming weeks. The Economic Assistance Coordinating Council must also approve the deal.
“We’re so excited to welcome them to the city,” said Mayor Arthur Vigeant. “We’re so excited they chose Marlborough.”
Revance – which employs 460 people – has been looking to expand in recent years and initially considered San Francisco's Bay Area for its new facility. The company was considering other areas in Massachusetts – including Northborough – and Ireland before selecting Marlborough.
City Councilor David Doucette called the proposed Campus Drive site a "marquee location."
“You guys lucked out as far as location goes,” he said.
Finance Committee Chairman John Irish said area towns and cities would be tripping over each other to attract a company like Revance to their community, especially during the economic downturn caused by the coronavirus pandemic.
Brian Blagg, vice president of engineering, facilities and supply chain at Revance, said the company’s primary objectives were to find a facility that meets all operational requirements at a location where the company can hire and retain exceptional talent, lower operating costs, operate in a stable and business-friendly environment with an improved tax structure and provide flexibility for future growth.
Marlborough, in recent years, has attracted several life science and biotech companies, bringing hundreds of new jobs to the region. Revance plans to hire 76 on-site, full-time employees at its new Marlborough facility by fiscal 2025 under the proposed tax increment financing deal.
"It’s nice to see some of these life science companies do well,” said Meredith Harris, executive director of the Marlborough Economic Development Corp.
Under the proposed tax increment financing deal, the real property exemption percentage would be 100% in fiscal 2022 and 2023, drop to 90% in fiscal years 2024 and 2025 and 85% in fiscal 2026. The real property exemption percentage will drop 5% each year from fiscal 2025 to fiscal 2031 and then 10% each year until the end of the deal in fiscal 2036.
The mayor and City Council President Michael Ossing said the deal will bring a new building to the city, generate much-needed tax revenue in the future and bring more jobs to Marlborough.
“I believe it’s a good deal for the city,” said Ossing.
The city currently has nine active tax increment financing deals with companies.
https://www.metrowestdailynews.com/story/news/2020/11/14/california-based-biotech-company-revance-gets-first-tif-approval/6233393002/
Enanta Pharmaceuticals to Host Conference Call on November 23 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2020
https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-to-Host-Conference-Call-on-November-23-at-430-p.m.-ET-to-Discuss-its-Financial-Results-for-its-Fiscal-Fourth-Quarter-and-Year-Ended-September-30-2020/default.aspx
Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q3 2020 Results - Earnings Call Transcript
https://seekingalpha.com/article/4387379-revance-therapeutics-inc-rvnc-ceo-mark-foley-on-q3-2020-results-earnings-call-transcript
Revance to Participate in the Stifel 2020 Virtual Healthcare Conference
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the Stifel 2020 Virtual Healthcare Conference, a fully virtual management access conference, taking place November 16-18.
President and Chief Executive Officer, Mark Foley, is scheduled to participate in a virtual fireside chat on Tuesday, November 17, at 11:00 a.m. PT / 2:00 p.m. ET.
https://finance.yahoo.com/news/revance-participate-stifel-2020-virtual-210500607.html
Revance to Participate in the Credit Suisse 29th Annual Healthcare Conference
....the company will participate in the Credit Suisse 29th Annual Healthcare Conference, a fully virtual management access conference, taking place November 9-12.
Chief Financial Officer, Toby Schilke, is scheduled to present on Tuesday, November 10, at 7:15 a.m. PT / 10:15 a.m. ET.
https://investors.revance.com/news-releases/news-release-details/revance-participate-credit-suisse-29th-annual-healthcare
Dew & Sir Flo will no longer have to venture to CALI for our in-house FAT & BEAUTIFUL facial treatments. Why, you ask? bc RVNC will soon have an outlet in Marlborough, Ma. employing 76.
Marlborough continues to add to reputation as biotech, life sciences hub
Excerpts:
Revance Therapeutics is seeking a tax increment financing deal to open a facility on Campus Drive. Sartorius announced plans last week to expand its North American manufacturing operations with a new facility on Locke Drive in Marlborough.
MARLBOROUGH – The city is continuing to add to its reputation as a hub for life science and biotech companies.
Newark, California-based Revance Therapeutics Inc. – a biotech company – is seeking a tax increment financing deal with the city to open a facility for commercial aseptic fill operations and research and development on Campus Drive.
Marlborough, in recent years, has attracted several life science and biotech companies, bringing hundreds of new jobs to the region.
“Due to its strong and growing commitment to the life sciences industry, Marlborough is rated a Platinum BioReadyTM Community by the Massachusetts Biotechnology Council (MassBio),” Mayor Arthur Vigeant wrote in a letter to the City Council. “This puts the city among the most favorable biotech destinations in the state, just 7% of Massachusetts communities have achieved ‘Platinum status.’ This investment equates to new job opportunities in our community and additional tax revenue ensuring the tax burden does not fall solely on our residents.”
Revance Therapeutics
Revance plans to lease a 79,000 square-foot single-tenant building on Campus Drive and construct parking facilities, the mayor said in his letter.
“Revance Therapeutics will create and maintain 76 permanent, full-time jobs available to qualified residents of Marlborough at the projected area,” Vigeant wrote. “Additionally, improvements to the Project Area are estimated in an initial capital investment of approximately $115 million in combined soft, real property and personal property costs.”
The company – which has about 430 employees – has been in talks with city leaders about opening a facility for the past few months.
Brian Blagg, vice president of engineering, facilities and supply chain, wrote a letter to city officials saying the company’s primary objectives were to find a facility that meets all operational requirements, a location where the company can hire and retain exceptional talent, lower operating costs, operate in a stable and business-friendly environment with an improved tax structure and provide flexibility for future growth.
“Revance Therapeutics is therefore requesting that you accept this letter as the formal letter of intent required under the Economic Development Incentive Program, (EDIP),” Blagg wrote in his letter.
https://marlborough.wickedlocal.com/news/20201102/marlborough-continues-to-add-to-reputation-as-biotech-life-sciences-hub
Revance to Release Third Quarter 2020 Financial Results on Monday, November 9, 2020
Conference Call Scheduled for Monday, November 9, 2020 at 4:30 p.m. ET
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA for Injection, today announced that the company will release third quarter 2020 financial results on Monday, November 9, 2020 after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT/4:30 p.m. ET on the same day to discuss the results and provide a business and pipeline update.
https://investors.revance.com/news-releases/news-release-details/revance-release-third-quarter-2020-financial-results-monday
FWIW -
Enanta price target raised to $107 from $104 at Roth Capital 16:19 ENTA Roth Capital analyst Zegbeh Jallah raised the firm's price target on Enanta to $107 from $104 and keeps a Buy rating on the shares ahead of the company's earnings report due on November 23. In addition to lowering her Q4 revenue projection, Jallah increased her view of the probability of success for Enanta's RSV program, EDP-938, to 30% from 25%, the analyst tells investors.
Read more at:
https://thefly.com/n.php?id=3181989
FWIW -
Enanta price target raised to $107 from $104 at Roth Capital 16:19 ENTA Roth Capital analyst Zegbeh Jallah raised the firm's price target on Enanta to $107 from $104 and keeps a Buy rating on the shares ahead of the company's earnings report due on November 23. In addition to lowering her Q4 revenue projection, Jallah increased her view of the probability of success for Enanta's RSV program, EDP-938, to 30% from 25%, the analyst tells investors.
Read more at:
https://thefly.com/n.php?id=3181989
Revance price target raised to $38 from $35 at Barclays. RVNC Barclays analyst Balaji Prasad raised the firm's price target on Revance to $38 from $35 and keeps an Overweight rating on the shares. The analyst expects to see signs of a broader recovery in Q3 for the U.S. Specialty Pharmaceuticals companies.
Read more at:
https://thefly.com/n.php?id=3181303
Revance price target raised to $38 from $35 at Barclays. RVNC Barclays analyst Balaji Prasad raised the firm's price target on Revance to $38 from $35 and keeps an Overweight rating on the shares. The analyst expects to see signs of a broader recovery in Q3 for the U.S. Specialty Pharmaceuticals companies.
Read more at:
https://thefly.com/n.php?id=3181303
FWIW -
Likely To Continue Rising To New Highs: Revance Therapeutics Inc. - 24 October
SIMPLEX TRADING LLC bought a fresh place in Revance Therapeutics Inc. (NASDAQ:RVNC). The institutional investor bought 7.7 thousand shares of the stock in a transaction took place on 9/30/2020. In another most recent transaction, which held on 9/30/2020, ENVESTNET ASSET MANAGEMENT, INC. bought approximately 357.00 shares of Revance Therapeutics Inc. In a separate transaction which took place on 7/31/2020, the institutional investor, WELLINGTON MANAGEMENT CO. LLP sold 13.1 thousand shares of the company’s stock. The total Institutional investors and hedge funds own 83.50% of the company’s stock.
https://bovnews.com/2020/10/24/likely-to-continue-rising-to-new-highs-revance-therapeutics-inc-rvnc-rent-a-center-inc-rcii/
Revance price target raised to $33 from $27 at H.C. Wainwright 06:14 RVNC H.C. Wainwright analyst Douglas Tsao raised the firm's price target on Revance to $33 from $27 and reiterates a Buy rating on the shares. The company presented a "strong" topline readout from its ASPEN 1 Phase 3 study evaluating DaxibotulinumtoxinA in the treatment of cervical dystonia, Tsao tells investors in a research note.
Read more at:
https://thefly.com/n.php?id=3175453
Amen - so far!
Revance price target raised to $33 from $27 at H.C. Wainwright 06:14 RVNC H.C. Wainwright analyst Douglas Tsao raised the firm's price target on Revance to $33 from $27 and reiterates a Buy rating on the shares. The company presented a "strong" topline readout from its ASPEN 1 Phase 3 study evaluating DaxibotulinumtoxinA in the treatment of cervical dystonia, Tsao tells investors in a research note.
Read more at:
https://thefly.com/n.php?id=3175453
ASPEN-1 Phase 3 Results Conference Call
October 14, 2020 5:30 AM PDT
Listen to Webcast
Supporting Materials
Click to View Infographic
Click to View Infographic
Click to View Video
Phase 3 Cervical Dystonia Presentation October 2020
Check it out -
https://investors.revance.com/events-webcasts/
Revance Reports Positive Results from ASPEN-1 Phase 3 Trial of DaxibotulinumtoxinA for Injection in Cervical Dystonia
Trial met primary and all secondary endpoints for both 125- and 250-Unit doses with high statistical significance -
- DaxibotulinumtoxinA for Injection was effective and generally well-tolerated in reducing the signs and symptoms for cervical dystonia, delivering up to a median duration of 24 weeks -
- Results suggest DaxibotulinumtoxinA for Injection has the potential to reduce frequency of cervical dystonia treatments by up to 50% annually -
- Global market opportunity for cervical dystonia is $340M1 -
- Conference call today at 8:30 a.m. ET -
Read more:
https://finance.yahoo.com/news/revance-reports-positive-results-aspen-120000497.html
Revance Reports Positive Results from ASPEN-1 Phase 3 Trial of DaxibotulinumtoxinA for Injection in Cervical Dystonia
Trial met primary and all secondary endpoints for both 125- and 250-Unit doses with high statistical significance -
- DaxibotulinumtoxinA for Injection was effective and generally well-tolerated in reducing the signs and symptoms for cervical dystonia, delivering up to a median duration of 24 weeks -
- Results suggest DaxibotulinumtoxinA for Injection has the potential to reduce frequency of cervical dystonia treatments by up to 50% annually -
- Global market opportunity for cervical dystonia is $340M1 -
- Conference call today at 8:30 a.m. ET -
Read more:
https://finance.yahoo.com/news/revance-reports-positive-results-aspen-120000497.html
Revance to Present Three New Abstracts Evaluating DaxibotulinumtoxinA for Injection & Two ePosters Evaluating the RHA® Colle...
October 06 2020 - 08:00AM
Two oral presentations highlighting new data on DaxibotulinumtoxinA for Injection from the SAKURA Phase 3 program, the largest aesthetic neuromodulator clinical program ever conducted for the treatment of glabellar (frown) lines –
- One oral presentation featuring new interim analysis data from a Phase 2a open-label study on the safety and efficacy of DaxibotulinumtoxinA for Injection for the treatment of lateral canthal lines (crow’s feet) –
- In addition, there will be two ePosters evaluating the properties of hyaluronic acid-based dermal fillers –
- Revance to also host ‘Innovative Technology for the Emerging Demand of Facial Dynamics’ virtual symposium at ASDS on Saturday, October 10, at 2:30 p.m. ET with Drs. Shannon Humphrey, Arthur Swift, Benji Dhillon and Charles Boyd -
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA for Injection, today announced three oral presentations and two ePosters at the American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting, October 9-11, 2020. Presented data will showcase novel findings from the SAKURA Phase 3 program evaluating DaxibotulinumtoxinA for Injection for the treatment of moderate or severe glabellar (frown) lines, as well as a 4-week interim analysis from the Phase 2a open-label study for the treatment of moderate to severe lateral canthal lines (LCL), commonly known as crow’s feet lines.
“These data underscore the potential of DaxibotulinumtoxinA for Injection to set a new standard in facial aesthetics treatments and advance our mission of transforming the patient experience,” said Roman Rubio, Senior Vice President of Clinical Development at Revance. “The data from the LCL study were used to optimize our Phase 2 open-label upper facial lines study, which we expect to report results from in the fourth quarter of 2020. Additionally, these findings support our overarching scientific platform as we continue to establish a new category of long-lasting neuromodulator products for our prestige aesthetics portfolio.”
The first presentation will report on the efficacy, duration, and safety of DaxibotulinumtoxinA for Injection in females across multiple age cohorts following the treatment of glabellar lines in the SAKURA program. This subgroup analysis demonstrated that the efficacy and duration of DaxibotulinumtoxinA for Injection for the treatment of glabellar lines is similarly high in adult females independent of age. The second presentation will highlight details from the SAKURA program in which DaxibotulinumtoxinA for Injection treated subjects showed substantial and progressive improvement in the severity of glabellar lines at rest following repeated treatment.
The final presentation will cover 4-week interim data from the Phase 2a open-label study in crow's feet. Data demonstrated that following treatment of LCLs with DaxibotulinumtoxinA for Injection, 88% of subjects achieved a score of none or mild at Week 4 in at least one treatment group. DaxibotulinumtoxinA for Injection appeared to be well tolerated at all dose levels. These results were previously announced by Revance in June 2020.
Oral Presentations:
DaxibotulinumtoxinA for Injection Demonstrates Consistent Efficacy, Duration, and Safety in Females Independent of Age: Subgroup Analysis from a Large, Phase 3 Program
Friday, October 9, 2020, 9:36 a.m. – 9:39 a.m. ET during the Session #1: Oral Abstracts.
Presenter: Glynis Ablon, M.D., FAAD, Dermatologist at Ablon Skin Institute and Research Center, Manhattan Beach, CA, and Associate Clinical Professor at University of California, Los Angeles, CA, USA
DaxibotulinumtoxinA for Injection–treated subjects show progressive improvement in static glabellar lines with repeated treatment
Friday, October 9, 2020, 9:42 a.m. – 9:45 a.m. ET during the Session #1: Oral Abstracts.
Presenter: Richard Glogau, M.D., Dermatologist at Glogau Dermatology, San Francisco, CA, and Clinical Professor of Dermatology University of California, San Francisco, CA, USA
DaxibotulinumtoxinA for Injection for Lateral Canthal Lines: A 4-week Interim Analysis
Friday, October 9, 2020, 9:39 a.m. – 9:42 a.m. ET during the Session #1: Oral Abstracts.
Presenter: Terrence Keaney, M.D., FAAD, Dermatologist at SkinDC Cosmetic Center, Arlington, VA, Assistant Clinical Faculty of Dermatology at George Washington University and Howard University, and Director of the Laser and Lipoatrophy Clinic at the Veterans Affairs Hospital, Washington, D.C.
ePosters:
Rheological Evaluation of the Dynamic Properties of Hyaluronic Acid-based Dermal Fillers
Authors: Vince Bertucci*, Conor Gallagher†, Jimmy Faivre‡, Kevin Legent‡, Mélanie Gallet‡, Elodie Tremblais‡, François Bourdon‡
Affiliations: *University of Toronto, Toronto, Ontario, Canada and private practice, Woodbridge, Ontario, Canada; †Revance Therapeutics, Inc., Newark, California; ‡Teoxane, Geneva, Switzerland
Evaluation of the Impact of Hyaluronic Acid (HA) Filler Manufacturing Technologies on HA Chain Degradation
Authors: Jay Mashburn†, Jimmy Faivre‡, François Bourdon‡
Affiliations: †Revance Therapeutics, Inc., Newark, California; ‡Teoxane, Geneva, Switzerland
Revance is anticipating the U.S. Food and Drug Administration (FDA) approval of DaxibotulinumtoxinA for Injection in glabellar (frown) lines in the fourth quarter of this year and is generating additional data in facial aesthetics, including three Phase 2 open-label trials in lateral canthal (crow’s feet), upper facial lines and forehead lines. The open-label Phase 2 trial of DaxibotulinumtoxinA for Injection for the treatment of upper facial lines – glabellar (frown), lateral canthal (crow’s feet), and forehead lines combined – completed enrollment in February 2020, and the company expects to report topline results in the fourth quarter of 2020.
https://ih.advfn.com/stock-market/NASDAQ/revance-therapeutics-RVNC/stock-news/83405176/revance-to-present-three-new-abstracts-evaluating
Revance to Present Three New Abstracts Evaluating DaxibotulinumtoxinA for Injection & Two ePosters Evaluating the RHA® Colle...
October 06 2020 - 08:00AM
Two oral presentations highlighting new data on DaxibotulinumtoxinA for Injection from the SAKURA Phase 3 program, the largest aesthetic neuromodulator clinical program ever conducted for the treatment of glabellar (frown) lines –
- One oral presentation featuring new interim analysis data from a Phase 2a open-label study on the safety and efficacy of DaxibotulinumtoxinA for Injection for the treatment of lateral canthal lines (crow’s feet) –
- In addition, there will be two ePosters evaluating the properties of hyaluronic acid-based dermal fillers –
- Revance to also host ‘Innovative Technology for the Emerging Demand of Facial Dynamics’ virtual symposium at ASDS on Saturday, October 10, at 2:30 p.m. ET with Drs. Shannon Humphrey, Arthur Swift, Benji Dhillon and Charles Boyd -
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA for Injection, today announced three oral presentations and two ePosters at the American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting, October 9-11, 2020. Presented data will showcase novel findings from the SAKURA Phase 3 program evaluating DaxibotulinumtoxinA for Injection for the treatment of moderate or severe glabellar (frown) lines, as well as a 4-week interim analysis from the Phase 2a open-label study for the treatment of moderate to severe lateral canthal lines (LCL), commonly known as crow’s feet lines.
“These data underscore the potential of DaxibotulinumtoxinA for Injection to set a new standard in facial aesthetics treatments and advance our mission of transforming the patient experience,” said Roman Rubio, Senior Vice President of Clinical Development at Revance. “The data from the LCL study were used to optimize our Phase 2 open-label upper facial lines study, which we expect to report results from in the fourth quarter of 2020. Additionally, these findings support our overarching scientific platform as we continue to establish a new category of long-lasting neuromodulator products for our prestige aesthetics portfolio.”
The first presentation will report on the efficacy, duration, and safety of DaxibotulinumtoxinA for Injection in females across multiple age cohorts following the treatment of glabellar lines in the SAKURA program. This subgroup analysis demonstrated that the efficacy and duration of DaxibotulinumtoxinA for Injection for the treatment of glabellar lines is similarly high in adult females independent of age. The second presentation will highlight details from the SAKURA program in which DaxibotulinumtoxinA for Injection treated subjects showed substantial and progressive improvement in the severity of glabellar lines at rest following repeated treatment.
The final presentation will cover 4-week interim data from the Phase 2a open-label study in crow's feet. Data demonstrated that following treatment of LCLs with DaxibotulinumtoxinA for Injection, 88% of subjects achieved a score of none or mild at Week 4 in at least one treatment group. DaxibotulinumtoxinA for Injection appeared to be well tolerated at all dose levels. These results were previously announced by Revance in June 2020.
Oral Presentations:
DaxibotulinumtoxinA for Injection Demonstrates Consistent Efficacy, Duration, and Safety in Females Independent of Age: Subgroup Analysis from a Large, Phase 3 Program
Friday, October 9, 2020, 9:36 a.m. – 9:39 a.m. ET during the Session #1: Oral Abstracts.
Presenter: Glynis Ablon, M.D., FAAD, Dermatologist at Ablon Skin Institute and Research Center, Manhattan Beach, CA, and Associate Clinical Professor at University of California, Los Angeles, CA, USA
DaxibotulinumtoxinA for Injection–treated subjects show progressive improvement in static glabellar lines with repeated treatment
Friday, October 9, 2020, 9:42 a.m. – 9:45 a.m. ET during the Session #1: Oral Abstracts.
Presenter: Richard Glogau, M.D., Dermatologist at Glogau Dermatology, San Francisco, CA, and Clinical Professor of Dermatology University of California, San Francisco, CA, USA
DaxibotulinumtoxinA for Injection for Lateral Canthal Lines: A 4-week Interim Analysis
Friday, October 9, 2020, 9:39 a.m. – 9:42 a.m. ET during the Session #1: Oral Abstracts.
Presenter: Terrence Keaney, M.D., FAAD, Dermatologist at SkinDC Cosmetic Center, Arlington, VA, Assistant Clinical Faculty of Dermatology at George Washington University and Howard University, and Director of the Laser and Lipoatrophy Clinic at the Veterans Affairs Hospital, Washington, D.C.
ePosters:
Rheological Evaluation of the Dynamic Properties of Hyaluronic Acid-based Dermal Fillers
Authors: Vince Bertucci*, Conor Gallagher†, Jimmy Faivre‡, Kevin Legent‡, Mélanie Gallet‡, Elodie Tremblais‡, François Bourdon‡
Affiliations: *University of Toronto, Toronto, Ontario, Canada and private practice, Woodbridge, Ontario, Canada; †Revance Therapeutics, Inc., Newark, California; ‡Teoxane, Geneva, Switzerland
Evaluation of the Impact of Hyaluronic Acid (HA) Filler Manufacturing Technologies on HA Chain Degradation
Authors: Jay Mashburn†, Jimmy Faivre‡, François Bourdon‡
Affiliations: †Revance Therapeutics, Inc., Newark, California; ‡Teoxane, Geneva, Switzerland
Revance is anticipating the U.S. Food and Drug Administration (FDA) approval of DaxibotulinumtoxinA for Injection in glabellar (frown) lines in the fourth quarter of this year and is generating additional data in facial aesthetics, including three Phase 2 open-label trials in lateral canthal (crow’s feet), upper facial lines and forehead lines. The open-label Phase 2 trial of DaxibotulinumtoxinA for Injection for the treatment of upper facial lines – glabellar (frown), lateral canthal (crow’s feet), and forehead lines combined – completed enrollment in February 2020, and the company expects to report topline results in the fourth quarter of 2020.
https://ih.advfn.com/stock-market/NASDAQ/revance-therapeutics-RVNC/stock-news/83405176/revance-to-present-three-new-abstracts-evaluating
Revance Therapeutics Inc (NASDAQ:RVNC) Short Interest Down 18.6% in September - OCTOBER 1 Report
Revance Therapeutics Inc (NASDAQ:RVNC) saw a significant drop in short interest in September. As of September 15th, there was short interest totalling 4,430,000 shares, a drop of 18.6% from the August 31st total of 5,440,000 shares. Based on an average daily volume of 589,800 shares, the days-to-cover ratio is currently 7.5 days.
https://www.marketbeat.com/instant-alerts/nasdaq-rvnc-options-data-report-2020-10/
Enanta Pharmaceuticals to Present at the 4th Annual H.C. Wainwright Virtual NASH Investor Conference
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 4th Annual H.C. Wainwright Virtual NASH Investor Conference on October 5, 2020 at 2:00 pm ET.
https://finance.yahoo.com/news/enanta-pharmaceuticals-present-4th-annual-110000382.html
ROTH Webinar - Enanta Pharmaceuticals (ENTA) - Registration
Topic
ROTH Webinar - Enanta Pharmaceuticals (ENTA) - Oct 1, 2020 – 1:00 PM (ET) / 10:00 AM (PT)
https://roth.zoom.us/webinar/register/WN_9ClZOYqRQtS3r_4Kc7kpag